

Euroz Hartleys Rottnest Island Institutional Conference

March 2024

www.botanixpharma.com

Botanix – accelerating towards commercialization of *Sofdra*™

DERMATOLOGY FOCUS	New treatments for underserved common skin diseases, with an initial focus on excessive sweating ("primary axillary hyperhidrosis")
TOPICALLY DRIVEN	Targeting key indications with topical (gel) treatments that are designed for safety, tolerability, and clinical efficacy
EXPERIENCED TEAM	US-based team that has been responsible for successful development and commercial launches of more than 30 dermatology drugs
NEW PRODUCT "SOFDRA"	Sofpironium Bromide <i>(Sofdra)</i> ¹ is the first and only new chemical entity developed for primary axillary hyperhidrosis (5% strength approved in Japan with solid sales) ²
TARGETING MID-24 FDA APPROVAL	Resubmission of NDA for approval was completed in late December 2023; targeting FDA approval in late June 2024



1. Sofdra (sofpironium bromide gel, 15%) is an investigational drug and is not FDA approved. The Sofdra brand name is under review by FDA.

2. ASX release May 4, 2022.

Corporate Overview

Well-funded to FDA approval, supported by leading life science institutional investors

ASX: BOT TRADING INFORMATION					
Share price	A\$0.185				
6-month low / high	A\$0.12/0.20				
Shares outstanding	1,563,437,373				
Market Capitalization	A\$275m				
Cash	A\$ 18.3m				
Debt	Nil				

SUBSTANTIAL SHAREHOLDERS

	Shareholder	%		
	Antares Capital	9.0%		
	Board and Management	7.0%		
	Тор 20	33%		

bota

PHARMACEUTICALS





Hyperhidrosis

A medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature



PHARMACFUTIC.


Hyperhidrosis affects ~16M people in the US¹

Results from overstimulation of the nervous system (a physiological not psychological condition)¹

90% of axillary (underarm) patients also have it in a second region¹

The most common age of onset for axillary hyperhidrosis patients is 12–17²

Market for treatments is ~\$US1.6B per annum projected to grow to \$US2.8B by 2030²



Our lead asset: Sofpironium Bromide (Sofdra)¹

The only new chemical entity developed specifically for the treatment of primary axillary hyperhidrosis

Met both co-primary endpoints in two Phase 3 trials²

- 60% of subjects had ≥2-point improvement in HDSM-Ax
- 65% had a significant reduction in GSP sweat production
- Met all secondary endpoints including clinically meaningful effect on 85% of patients
 - ≥1-point improvement in HDSM-Ax
 - Statistically significant improvement

Favorable tolerability and safety profile³

Well-tolerated with adverse events that were mostly mild or moderate, and events were transient



Sofdra (sofpironium bromide gel, 15%) is an investigational drug and is not FDA approved. The Sofdra brand name is under review by FDA

Two identical randomized, double-blinded, vehicle-controlled Phase 3 trials for primary axillary hyperhidrosis (pooled; sofpironium bromide gel, 15% n=353; vehicle n=348)
Dry mouth and blurred vision were the predominant treatment-emergent adverse events at 14.4% and 8.5%, respectively, and are common among anticholinergic drugs

Innovative launch strategy to accelerate adoption following approval

Rapidly establish *Sofdra* as a safe and effective first line treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older



Drive Derm adoption through comprehensive engagement around a compelling clinical story



Engage and motivate patients to take control of their hyperhidrosis by visiting a telemedicine doctor for a diagnosis and prescription



Maximize favorable coverage



Provide patient access and immediate fulfillment through telemedicine and pharmacy network with mail-order fulfillment to drive trial while ensuring compliance



Hire and train a highly effective Sales Force

Planned launch activities targeting high prescribers of HH products

bota

PHARMACEUTICALS

In-office rep activities will include video, animation, and printed leave behinds

Digital advertising to drive targeted prescribers to SofdraHCP.com



bota

PHARMACEUTICALS

Patient launch activities to target active HH information seekers

Planned search engine optimization/marketing and all materials will drive patients to Sofdra.com Planned social media and digital advertising will drive patients to quiz on Sofdra.com



Images of marketing materials are for representative purposes only

Proactive, pre-approval engagement with Payors with >200K lives

Optimize access ahead of planned launch

	Rx Con PBM	Account Lives		Lives	Rnk	Clin Pro	es	
6	CVS	CVS Caremarl	CVS Caremark - Advanced Control, Performance Standard Control, Value 1,8		1	Yes		
Ē	EXPRESS		Express Scripts - High Performance, Basic 1,718,678			Yes		
	EMISAR ASCENT	Rx Con PBM Account			Lives	5	Rnk	Clin Pres
	ASCENT	ZINC	CVS Caremark - Advanced Control, Performance Standard	30,650,000		1	Yes	
6	N/A	ASCENT	Express Scripts - National Preferred Formulary		26,709,534		1	Yes
Q	ZINC	EMISAR	OptumRX Premium Standard, Value, Select Standard		15,435,000		1	Yes
P	PROCARE	ZINC	Anthem Essential HMO, PPO, National, Traditi	12,833,835		2	Yes	
U	PRIME	EMISAR	United Healthcare- Access, Advantage, Choice, Esse	12,658,000		2	Yes	
		ASCENT	Cigna- Advantage, National Preferred, Perform	8,760,900		2	No	
	ASCENT	KAISER	Kaiser Permanente	8,303,484		1	Yes	
	EMISAR	TRICARE	TriCare		7,214,213		2	Yes
	EMISAR	ZINC	AETNA- Open, Standard, Fully Insured		5,958,336		2	Yes
$(\square$	DIVIDEND	CVS	(FEHBP)- Basic, Focus, Standard		5,330	,051	1	Yes
9		DoD	DEPARTMENT OF VETERANS AFFAIRS		4,701	,838	2	Yes
	NAVITUS	PRIME	BCBS IL/ Tx/NM/MT (HCSC)- HMO or PPO Enhanced, Perfor	mance, Multi Tier	4,575	,000	2	No
		ASCENT	Prime Therapeutics		2,460	,000	2	Yes
	\supset)	PRIME	BCBS FL- HMO, PPO Multi Tier		2,125	,000	2	No

- Completed Payor profiles and engagement plan
- Engaged target Payors around unmet need in primary axillary hyperhidrosis and *Sofdra* value proposition
- Confirmed hyperhidrosis reimbursement status as medical condition
- Commenced initial discussions with target Payors responsible for 80% of covered lives

PHARMACEUTICAL

Docs will e-prescribe directly to our national pharmacy network

Instructions are provided to patient in doctor's office when prescription is written

Strong value and convenience messaging includes capping patient's out-of-pocket cost

QR code to enter instantly into digital space and begin interaction with our pharmacy network

Pharmacy mails Sofdra the same day that the patient completes their intake form



Images of marketing materials are for representative purposes only


Territories created based on prescriptions and HH diagnosis data


National programs focused on educating physicians and office staff

PHARMACEUTICALS

Territories aligned with prescriber and HH Data

Targeted cities based on prescriber and HH data





11

Focused pre-launch period ahead

- FDA approval targeted for late June 2024
- The issue being considered by the FDA is related to patient Instructions For Use—no efficacy, safety or manufacturing issues remain
- Commercial preparation is accelerating in anticipation of FDA approval
- Company is funded through approval and has multiple commercialization options



Important Notice & Disclaimer

1. Summary information

This presentation has been prepared by Botanix Pharmaceuticals Ltd ("Botanix") and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation ("Presentation") (unless otherwise indicated).

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Reliance should not be placed on information or opinions contained in this Presentation, and Botanix does not have any obligation to finalise, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix's other periodic and continuous disclosure announcements lodged with the ASX, which are available at www2.asx.com.au or at https://botanixpharma.com/category/asx-releases/.

2. Not an offer

Neither this Presentation nor any of its contents will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

3. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

4. Financial data

All dollar values are in United States dollars (\$ or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

5. Forward-looking statements and forecasts

This Presentation contains certain "forward-looking statements" and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions are to indications, guidances or future earnings, guidance and estimates. Forward-looking statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained assumptions as to future events which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Any such forward looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Performance of any of the activities mentioned in this Presentation are dependent on funding being available at the relevant time and the activities may therefore change, or not be undertaken at all.

Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Botanix may also change the order or nature of the activities at its discretion and without notice.

6. No liability

The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents have authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, Botanix and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents:

expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

Operations:

150 N Radnor Chester Road Suite A210 Wayne PA 19087

Corporate Office: D2, 661 Newcastle Street Leederville W. Australia 6007



Authorised for release by Vince Ippolito, Executive Chairman